木氧化嗜酸性杆菌是一种需氧菌,过氧化氢酶阳性,非颜料形成,革兰氏阴性,和能动的细菌。它可能在囊性纤维化和非囊性纤维化患者中引起广泛的人类感染。然而,开发一种安全的预防或治疗方案,以防止木酮。本研究旨在使用免疫信息学技术构建基于表位的候选疫苗。A.xylosoxidans从拉合尔的一家汽车车间分离出来,并通过16SrRNA扩增和生物信息学分析证实了其鉴定。对于疫苗构建体,选择具有GenBank登录号AKP90890.1和AKP90355.1的两个蛋白质靶标。两种蛋白质都表现出抗原性,得分分别为0.757和0.580,并根据IC50值分别使用ANN4.0和NN-比对2.3表位预测方法对MHCI和MHCII表位进行选择,并对预测的表位进行抗原性分析,变应原性和致病性。疫苗构建体显示出结构稳定性,热稳定性,溶解度,和亲水性。该疫苗每mm3产生250个B记忆细胞和大约16,000个IgM+IgG计数,表明针对木氧氧曲霉的有效免疫应答。此外,候选疫苗与模式识别受体Toll样受体5稳定相互作用,置信度得分为0.98。这些结果突出了设计的候选疫苗的效力,这表明它有可能承受严格的体外和体内临床试验。这种基于表位的疫苗可以作为第一个针对木酮氧化杆菌感染的预防性免疫疗法,解决这种细菌的健康和经济负担。这些发现证明了在疫苗开发中采用免疫信息学工具的价值,为更精确和定制的方法来对抗微生物威胁铺平了道路。
Achromobacter xylosoxidans is an aerobic, catalase-positive, non-pigment-forming, Gram-negative, and motile bacterium. It potentially causes a wide range of human infections in cystic fibrosis and non-cystic fibrosis patients. However, developing a safe preventive or therapeutic solution against A. xylosoxidans remains challenging. This study aimed to construct an epitope-based vaccine candidate using immunoinformatic techniques. A. xylosoxidans was isolated from an auto workshop in Lahore, and its identification was confirmed through 16S rRNA amplification and bioinformatic analysis. Two protein targets with GenBank accession numbers AKP90890.1 and AKP90355.1 were selected for the vaccine construct. Both proteins exhibited antigenicity, with scores of 0.757 and 0.580, respectively and the epitopes were selected based on the IC50 value using the ANN 4.0 and NN-align 2.3 epitope prediction method for MHC I and MHC II epitopes respectively and predicted epitopes were analyzed for antigenicity, allergenicity and pathogenicity. The vaccine construct demonstrated structural stability, thermostability, solubility, and hydrophilicity. The vaccine produced 250 B-memory cells per mm3 and approximately 16,000 IgM + IgG counts, indicating an effective immune response against A. xylosoxidans. Moreover, the vaccine candidate interacted stably with toll-like receptor 5, a pattern recognition receptor, with a confidence score of 0.98. These results highlight the potency of the designed vaccine candidate, suggesting its potential to withstand rigorous in vitro and in vivo clinical trials. This epitope-based vaccine could serve as the first preventive immunotherapy against A. xylosoxidans infections, addressing this bacterium\'s health and financial burdens. The findings demonstrate the value of employing immunoinformatic tools in vaccine development, paving the way for more precise and tailored approaches to combating microbial threats.